Addressing a weakness of anticancer therapy with mitosis inhibitors: Mitotic slippage

Mitosis inhibitors, which include antimicrotubule drugs, are chemotherapy agents that induce the arrest and apoptosis of mitotic cells. Mitotic slippage, in which mitotically arrested cells exit mitosis, limits the effectiveness of mitosis inhibitors. We have discovered that the CRL2(ZYG11A/B) ubiqu...

Descripción completa

Detalles Bibliográficos
Autores principales: Balachandran, Riju S., Kipreos, Edward T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2017
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5383364/
https://www.ncbi.nlm.nih.gov/pubmed/28401182
http://dx.doi.org/10.1080/23723556.2016.1277293
_version_ 1782520272394387456
author Balachandran, Riju S.
Kipreos, Edward T.
author_facet Balachandran, Riju S.
Kipreos, Edward T.
author_sort Balachandran, Riju S.
collection PubMed
description Mitosis inhibitors, which include antimicrotubule drugs, are chemotherapy agents that induce the arrest and apoptosis of mitotic cells. Mitotic slippage, in which mitotically arrested cells exit mitosis, limits the effectiveness of mitosis inhibitors. We have discovered that the CRL2(ZYG11A/B) ubiquitin ligase promotes mitotic slippage. The combination of antimicrotubule drugs and a CRL2(ZYG11A/B) inhibitor prevents mitotic slippage to increase antimitotic efficacy.
format Online
Article
Text
id pubmed-5383364
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-53833642018-01-05 Addressing a weakness of anticancer therapy with mitosis inhibitors: Mitotic slippage Balachandran, Riju S. Kipreos, Edward T. Mol Cell Oncol Author's View Mitosis inhibitors, which include antimicrotubule drugs, are chemotherapy agents that induce the arrest and apoptosis of mitotic cells. Mitotic slippage, in which mitotically arrested cells exit mitosis, limits the effectiveness of mitosis inhibitors. We have discovered that the CRL2(ZYG11A/B) ubiquitin ligase promotes mitotic slippage. The combination of antimicrotubule drugs and a CRL2(ZYG11A/B) inhibitor prevents mitotic slippage to increase antimitotic efficacy. Taylor & Francis 2017-01-05 /pmc/articles/PMC5383364/ /pubmed/28401182 http://dx.doi.org/10.1080/23723556.2016.1277293 Text en © 2017 The Author(s). Published with license by Taylor & Francis Group, LLC http://creativecommons.org/licenses/by/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The moral rights of the named author(s) have been asserted.
spellingShingle Author's View
Balachandran, Riju S.
Kipreos, Edward T.
Addressing a weakness of anticancer therapy with mitosis inhibitors: Mitotic slippage
title Addressing a weakness of anticancer therapy with mitosis inhibitors: Mitotic slippage
title_full Addressing a weakness of anticancer therapy with mitosis inhibitors: Mitotic slippage
title_fullStr Addressing a weakness of anticancer therapy with mitosis inhibitors: Mitotic slippage
title_full_unstemmed Addressing a weakness of anticancer therapy with mitosis inhibitors: Mitotic slippage
title_short Addressing a weakness of anticancer therapy with mitosis inhibitors: Mitotic slippage
title_sort addressing a weakness of anticancer therapy with mitosis inhibitors: mitotic slippage
topic Author's View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5383364/
https://www.ncbi.nlm.nih.gov/pubmed/28401182
http://dx.doi.org/10.1080/23723556.2016.1277293
work_keys_str_mv AT balachandranrijus addressingaweaknessofanticancertherapywithmitosisinhibitorsmitoticslippage
AT kipreosedwardt addressingaweaknessofanticancertherapywithmitosisinhibitorsmitoticslippage

Ejemplares similares